Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir±Ribavirin treatment in HCV infected chronic hemodialysis patients: A single center experience

Documenti analoghi

• Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir±Ribavirin treatment in HCV infected chronic hemodialysis patients: A single center experience
  di: Nilay Danis, et al.
  Pubblicazione: (2019-07-01)
• Efficacy and safety of Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin in chronic hepatitis C patients with chronic renal failure
  di: Fatih Güzelbulut, et al.
  Pubblicazione: (2019-07-01)
• Everolimus Toxicity in a Kidney Transplant Recipient Treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Chronic Hepatitis C
  di: Mete Akın, et al.
  Pubblicazione: (2020-02-01)
• Real-world efficacy, safety and clinical outcomes of ombitasvir/ paritaprevir/ ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: Turkey experience
  di: Bilgehan Aygen, et al.
  Pubblicazione: (2019-07-01)
• Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
  di: Bilgehan Aygen, et al.
  Pubblicazione: (2020-04-01)